US Capitol Capsule: Barriers to PCSK9s use: What to expect

While Sanofi and Regeneron Pharmaceuticals said the FDA granted what the companies perceived as a "pretty broad label" for Praluent (alirocumab) – the first proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitor approved in the US to lower low density lipoprotein cholesterol (LDL-C) when statins are not enough – the firms said they anticipated some barriers to the drug's use in the US.

And what goes for Praluent also could be true for Amgen's Repatha (evolocumab), which is expected to also gain US...